Basal ganglia iron in tardive dyskinesia: an MRI study.
Alterations in brain iron could play an important role in the development of tardive dyskinesia in patients receiving neuroleptic medication. To test this hypothesis, magnetic resonance imaging scans of the brain were performed on 21 chronic schizophrenic patients. Ten patients met research diagnostic criteria for persistent tardive dyskinesia, and 11 were free of tardive dyskinesia. All patients had received long-term neuroleptic treatment and were on a stable neuroleptic dose for at least 3 months before scanning. The signal intensity of basal ganglia structures was obtained as a quantitative estimate of brain iron content. No difference was found in the signal intensity ratios between the two groups. This suggests that iron deposition in the basal ganglia, at least as assessed by this measure, does not play a role in the pathophysiology of tardive dyskinesia.
Elkashef
A M
AM
Neuropsychiatry Branch, NIMH, St. Elizabeths Hospital, Washington, DC 20032.
Egan
M F
MF
Frank
J A
JA
Hyde
T M
TM
Lewis
B K
BK
Wyatt
R J
RJ
D000328:Adult; D001479:Basal Ganglia / Q000378:metabolism*; D004292:Dominance, Cerebral / Q000187:drug effects / Q000502:physiology; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism*; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007501:Iron / Q000378:metabolism*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D008972:Molindone / Q000009:adverse effects / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy; D012565:Schizophrenic Psychology
D007501:Iron; D006220:Haloperidol; D008972:Molindone